Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

@inproceedings{Sweetlove2015InhibitorsOP,
  title={Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth},
  author={Melanie Sweetlove and Emma Wrightson and S. V. Kolekar and Gordon William Rewcastle and B. C. Baguley and P. R. Shepherd and Stephen M F Jamieson},
  booktitle={Front. Oncol.},
  year={2015}
}
BRAF and MEK inhibitors have improved outcomes for patients with BRAF-mutant melanoma, but their efficacy is limited by both intrinsic and acquired resistances. Activation of the PI3K pathway can mediate resistance to these agents, providing a strong rationale for combination therapy in melanoma. Here, a panel of nine low-passage human metastatic melanoma… CONTINUE READING